Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 116, Issue 4, Pages 811-815Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000001046
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [T32-DK007038]
- National Institutes of Health/NIDDK [K08-DK095951]
- Crohn's and Colitis Foundation
- Takeda Pharmaceuticals USA
- Janssen Pharmaceuticals
- National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K08-DK119475]
- National Institutes of Health
- NIH [R01CA242558, P30-DK050306, U54CA163004]
- University of Colorado Department of Medicine Outstanding Early Scholars Award
- Consultant for Medtronic
- Boston Scientific
- Interpace
- Cernostics
Ask authors/readers for more resources
Using the National Cancer Database, this study found that facilities with higher annual esophageal adenocarcinoma (EAC) case volume had better survival rates compared to lower volume facilities. The results suggest centralization of care for EAC patients at facilities with high annual case volume for improved outcomes.
INTRODUCTION: Using the National Cancer Database, we assessed the relationship between facility overall esophageal adenocarcinoma (EAC) case volume and survival. METHODS: We categorized facilities into volume quintiles based on annual EAC patient volume and performed a multivariable Cox proportional hazards regression between facility patient volume and survival. RESULTS: In a cohort of 116,675 patients, facilities with higher vs lower (>= 25 vs 1-4 cases) annual EAC patient volume demonstrated improved survival (adjusted hazard ratio: 0.80. 95% confidence interval: 0.70-0.91). DISCUSSION: This robust volume-outcome effect calls for centralization of care for EAC patients at high annual case volume facilities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
